Aluminium-adjuvanted vaccines transiently increase aluminium levels in murine brain tissue

Pharmacol Toxicol. 1992 Apr;70(4):278-80. doi: 10.1111/j.1600-0773.1992.tb00471.x.


Aluminium is widely used as an adjuvant in human vaccines, and children can often receive up to 3.75 mg of parenteral aluminium during the first six months of life. We show that intraperitoneal injection of aluminium adsorbed vaccines into mice causes a transient rise in brain tissue aluminium levels peaking around the second and third day after injection. This rise is not seen in the saline control group of animals or with vaccine not containing aluminium. It is likely that aluminium is transported to the brain by the iron-binding protein transferrin and enters the brain via specific transferrin receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / administration & dosage
  • Adjuvants, Immunologic / pharmacokinetics*
  • Aluminum / administration & dosage
  • Aluminum / pharmacokinetics*
  • Animals
  • Brain / metabolism*
  • Diphtheria Toxoid / administration & dosage*
  • Diphtheria-Tetanus Vaccine
  • Diphtheria-Tetanus-Pertussis Vaccine / administration & dosage*
  • Drug Combinations
  • Mice
  • Tetanus Toxoid / administration & dosage*
  • Time Factors


  • Adjuvants, Immunologic
  • Diphtheria Toxoid
  • Diphtheria-Tetanus Vaccine
  • Diphtheria-Tetanus-Pertussis Vaccine
  • Drug Combinations
  • Tetanus Toxoid
  • Aluminum